325 related articles for article (PubMed ID: 25542711)
1. [Antiphosphatidylethanolamine antibody as a marker of antiphospholipid syndrome?].
Yelnik CM; Dubucquoi S; Houfflin-Debarge V; Lambert M
Presse Med; 2015 Mar; 44(3):284-91. PubMed ID: 25542711
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of antiphosphatidylethanolamine antibodies in the so-called "seronegative antiphospholipid syndrome".
Sanmarco M
Autoimmun Rev; 2009 Dec; 9(2):90-2. PubMed ID: 19306951
[TBL] [Abstract][Full Text] [Related]
3. [Which place of antiphosphatidylethanolamine antibodies research in seronegative antiphospholipid syndrome suspicion?].
Billoir P; Miranda S; Abboud J; Armengol G; Levesque H; Benhamou Y; Le Cam Duchez V
Rev Med Interne; 2019 Jun; 40(6):351-354. PubMed ID: 30905593
[TBL] [Abstract][Full Text] [Related]
4. Seronegative Antiphospholipid Syndrome with Anti-phosphatidylethanolamine Antibody in a Boy.
Asano T; Narazaki H; Kaizu K; Kuwabara K; Fujino O; Itoh Y
J Nippon Med Sch; 2015; 82(2):117-20. PubMed ID: 25959205
[TBL] [Abstract][Full Text] [Related]
5. The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE).
Bertolaccini ML; Murru V; Sciascia S; Sanna G; Khamashta MA
Thromb Res; 2012 Dec; 130(6):914-8. PubMed ID: 23079292
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses.
Sanmarco M; Alessi MC; Harle JR; Sapin C; Aillaud MF; Gentile S; Juhan-Vague I; Weiller PJ
Thromb Haemost; 2001 May; 85(5):800-5. PubMed ID: 11372671
[TBL] [Abstract][Full Text] [Related]
7. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS').
Rodriguez-Garcia JL; Bertolaccini ML; Cuadrado MJ; Sanna G; Ateka-Barrutia O; Khamashta MA
Ann Rheum Dis; 2012 Feb; 71(2):242-4. PubMed ID: 21953349
[TBL] [Abstract][Full Text] [Related]
8. Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome.
Sanmarco M; Boffa MC
Lupus; 2009 Sep; 18(10):920-3. PubMed ID: 19671793
[TBL] [Abstract][Full Text] [Related]
9. The outcome of ELISA for antiphosphatidylethanolamine antibodies is dependent on the composition of phosphatidylethanolamine.
Hou S; Harper PE; Bardin N; Zhao M
J Immunol Methods; 2017 Jan; 440():27-34. PubMed ID: 27784626
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and pregnancy outcome in antiphospholipid syndrome patients with history of severe pregnancy complications.
Matsuki Y; Atsumi T; Yamaguchi K; Hisano M; Arata N; Oku K; Watanabe N; Sago H; Takasaki Y; Murashima A
Mod Rheumatol; 2015 Mar; 25(2):215-8. PubMed ID: 25146551
[TBL] [Abstract][Full Text] [Related]
11. Does seronegative obstetric APS exist? "pro" and "cons".
Conti F; Andreoli L; Crisafulli F; Mancuso S; Truglia S; Tektonidou MG
Autoimmun Rev; 2019 Dec; 18(12):102407. PubMed ID: 31639518
[TBL] [Abstract][Full Text] [Related]
12. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases.
Berard M; Chantome R; Marcelli A; Boffa MC
J Rheumatol; 1996 Aug; 23(8):1369-74. PubMed ID: 8856615
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome.
Arachchillage DR; Machin SJ; Mackie IJ; Cohen H
Thromb Haemost; 2015 Jan; 113(1):13-9. PubMed ID: 25318976
[TBL] [Abstract][Full Text] [Related]
14. The contribution of antiphosphatidylethanolamine antibodies in the diagnosis of the antiphospholipid syndrome.
Sanmarco M; Bardin N
Lupus; 2012 Jun; 21(7):727-8. PubMed ID: 22635214
[TBL] [Abstract][Full Text] [Related]
15. Antiphospholipid antibodies: evaluation of the thrombotic risk.
Devreese KM
Thromb Res; 2012 Oct; 130 Suppl 1():S37-40. PubMed ID: 23026657
[TBL] [Abstract][Full Text] [Related]
16. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies.
Sanmarco M; Gayet S; Alessi MC; Audrain M; de Maistre E; Gris JC; de Groot PG; Hachulla E; Harlé JR; Sié P; Boffa MC
Thromb Haemost; 2007 Jun; 97(6):949-54. PubMed ID: 17549297
[TBL] [Abstract][Full Text] [Related]
17. Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome.
Noureldine MHA; Nour-Eldine W; Khamashta MA; Uthman I
Semin Arthritis Rheum; 2019 Apr; 48(5):860-866. PubMed ID: 30217394
[TBL] [Abstract][Full Text] [Related]
18. Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome.
Staub HL; Bertolaccini ML; Khamashta MA
Autoimmun Rev; 2012 Dec; 12(2):230-4. PubMed ID: 22796282
[TBL] [Abstract][Full Text] [Related]
19. Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study.
Hisada R; Kato M; Sugawara E; Fujieda Y; Oku K; Bohgaki T; Amengual O; Yasuda S; Atsumi T
J Thromb Haemost; 2017 Sep; 15(9):1782-1787. PubMed ID: 28662299
[TBL] [Abstract][Full Text] [Related]
20. Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study).
Bazzan M; Vaccarino A; Stella S; Sciascia S; Montaruli B; Bertero MT; Carignola R; Roccatello D;
Lupus; 2016 Apr; 25(5):479-85. PubMed ID: 26657216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
